Evidence map›Paper›PMID 38543087›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

PK Modeling of L-4-Boronophenylalanine and Development of Bayesian Predictive Platform for L-4-Boronophenylalanine PKs for Boron Neutron Capture Therapy.

Woohyoung Kim, Ji Yeong Won, Jungyu Yi, Seung Chan Choi, Sang Min Lee, Kyungran Mun, Hyeong-Seok Lim

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Woohyoung KimClinical Development, Dawonmedax Co., Ltd., Seoul 06735, Republic of Korea.ORCID 0000-0002-1323-8443
Ji Yeong WonClinical Development, Dawonmedax Co., Ltd., Seoul 06735, Republic of Korea.
Jungyu YiTreatment Planning System, Dawonmedax Co., Ltd., Seoul 06735, Republic of Korea.
Seung Chan ChoiDepartment of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Pungnap-2-dong, Seoul 05505, Republic of Korea.
Sang Min LeeDepartment of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Pungnap-2-dong, Seoul 05505, Republic of Korea.
Kyungran MunDepartment of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Pungnap-2-dong, Seoul 05505, Republic of Korea.
Hyeong-Seok LimDepartment of Clinical Pharmacology and Therapeutics, Asan Medical Center, University of Ulsan College of Medicine, Pungnap-2-dong, Seoul 05505, Republic of Korea.ORCID 0000-0003-1420-8200
Ulsan College · KR

Funding

Dawonmedax Co. Ltd. No specific grant number provided. It is funded by the private institute
6 · The paper itself

Abstract

L-4-[(

Indexed as

boron neutron capture therapyboronophenylalaninenonlinear mixed effect modelingPK modeling

Identifiers

PMID38543087
PMCPMC10975701
OpenAlexW4392197574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.